Chapter/Section Purchase

1 Study Coverage
1.1 Immune Checkpoint Agents Product Introduction
1.2 Market by Type
1.2.1 Global Immune Checkpoint Agents Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Anti-PD-L1 Drug
1.2.3 Anti-PD-1 Drug
1.2.4 CTLA4
1.3 Market by Application
1.3.1 Global Immune Checkpoint Agents Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 BreastCancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancers
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Immune Checkpoint Agents Sales Estimates and Forecasts 2017-2028
2.2 Global Immune Checkpoint Agents Revenue Estimates and Forecasts 2017-2028
2.3 Global Immune Checkpoint Agents Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Immune Checkpoint Agents Sales by Region
2.4.1 Global Immune Checkpoint Agents Sales by Region (2017-2022)
2.4.2 Global Sales Immune Checkpoint Agents by Region (2023-2028)
2.5 Global Immune Checkpoint Agents Revenue by Region
2.5.1 Global Immune Checkpoint Agents Revenue by Region (2017-2022)
2.5.2 Global Immune Checkpoint Agents Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Immune Checkpoint Agents Sales by Manufacturers
3.1.1 Global Top Immune Checkpoint Agents Manufacturers by Sales (2017-2022)
3.1.2 Global Immune Checkpoint Agents Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Immune Checkpoint Agents in 2021
3.2 Global Immune Checkpoint Agents Revenue by Manufacturers
3.2.1 Global Immune Checkpoint Agents Revenue by Manufacturers (2017-2022)
3.2.2 Global Immune Checkpoint Agents Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Immune Checkpoint Agents Revenue in 2021
3.3 Global Immune Checkpoint Agents Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Immune Checkpoint Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Immune Checkpoint Agents Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Immune Checkpoint Agents Sales by Type
4.1.1 Global Immune Checkpoint Agents Historical Sales by Type (2017-2022)
4.1.2 Global Immune Checkpoint Agents Forecasted Sales by Type (2023-2028)
4.1.3 Global Immune Checkpoint Agents Sales Market Share by Type (2017-2028)
4.2 Global Immune Checkpoint Agents Revenue by Type
4.2.1 Global Immune Checkpoint Agents Historical Revenue by Type (2017-2022)
4.2.2 Global Immune Checkpoint Agents Forecasted Revenue by Type (2023-2028)
4.2.3 Global Immune Checkpoint Agents Revenue Market Share by Type (2017-2028)
4.3 Global Immune Checkpoint Agents Price by Type
4.3.1 Global Immune Checkpoint Agents Price by Type (2017-2022)
4.3.2 Global Immune Checkpoint Agents Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Immune Checkpoint Agents Sales by Application
5.1.1 Global Immune Checkpoint Agents Historical Sales by Application (2017-2022)
5.1.2 Global Immune Checkpoint Agents Forecasted Sales by Application (2023-2028)
5.1.3 Global Immune Checkpoint Agents Sales Market Share by Application (2017-2028)
5.2 Global Immune Checkpoint Agents Revenue by Application
5.2.1 Global Immune Checkpoint Agents Historical Revenue by Application (2017-2022)
5.2.2 Global Immune Checkpoint Agents Forecasted Revenue by Application (2023-2028)
5.2.3 Global Immune Checkpoint Agents Revenue Market Share by Application (2017-2028)
5.3 Global Immune Checkpoint Agents Price by Application
5.3.1 Global Immune Checkpoint Agents Price by Application (2017-2022)
5.3.2 Global Immune Checkpoint Agents Price Forecast by Application (2023-2028)
6 North America
6.1 North America Immune Checkpoint Agents Market Size by Type
6.1.1 North America Immune Checkpoint Agents Sales by Type (2017-2028)
6.1.2 North America Immune Checkpoint Agents Revenue by Type (2017-2028)
6.2 North America Immune Checkpoint Agents Market Size by Application
6.2.1 North America Immune Checkpoint Agents Sales by Application (2017-2028)
6.2.2 North America Immune Checkpoint Agents Revenue by Application (2017-2028)
6.3 North America Immune Checkpoint Agents Market Size by Country
6.3.1 North America Immune Checkpoint Agents Sales by Country (2017-2028)
6.3.2 North America Immune Checkpoint Agents Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Immune Checkpoint Agents Market Size by Type
7.1.1 Europe Immune Checkpoint Agents Sales by Type (2017-2028)
7.1.2 Europe Immune Checkpoint Agents Revenue by Type (2017-2028)
7.2 Europe Immune Checkpoint Agents Market Size by Application
7.2.1 Europe Immune Checkpoint Agents Sales by Application (2017-2028)
7.2.2 Europe Immune Checkpoint Agents Revenue by Application (2017-2028)
7.3 Europe Immune Checkpoint Agents Market Size by Country
7.3.1 Europe Immune Checkpoint Agents Sales by Country (2017-2028)
7.3.2 Europe Immune Checkpoint Agents Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Immune Checkpoint Agents Market Size by Type
8.1.1 Asia Pacific Immune Checkpoint Agents Sales by Type (2017-2028)
8.1.2 Asia Pacific Immune Checkpoint Agents Revenue by Type (2017-2028)
8.2 Asia Pacific Immune Checkpoint Agents Market Size by Application
8.2.1 Asia Pacific Immune Checkpoint Agents Sales by Application (2017-2028)
8.2.2 Asia Pacific Immune Checkpoint Agents Revenue by Application (2017-2028)
8.3 Asia Pacific Immune Checkpoint Agents Market Size by Region
8.3.1 Asia Pacific Immune Checkpoint Agents Sales by Region (2017-2028)
8.3.2 Asia Pacific Immune Checkpoint Agents Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Immune Checkpoint Agents Market Size by Type
9.1.1 Latin America Immune Checkpoint Agents Sales by Type (2017-2028)
9.1.2 Latin America Immune Checkpoint Agents Revenue by Type (2017-2028)
9.2 Latin America Immune Checkpoint Agents Market Size by Application
9.2.1 Latin America Immune Checkpoint Agents Sales by Application (2017-2028)
9.2.2 Latin America Immune Checkpoint Agents Revenue by Application (2017-2028)
9.3 Latin America Immune Checkpoint Agents Market Size by Country
9.3.1 Latin America Immune Checkpoint Agents Sales by Country (2017-2028)
9.3.2 Latin America Immune Checkpoint Agents Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Immune Checkpoint Agents Market Size by Type
10.1.1 Middle East and Africa Immune Checkpoint Agents Sales by Type (2017-2028)
10.1.2 Middle East and Africa Immune Checkpoint Agents Revenue by Type (2017-2028)
10.2 Middle East and Africa Immune Checkpoint Agents Market Size by Application
10.2.1 Middle East and Africa Immune Checkpoint Agents Sales by Application (2017-2028)
10.2.2 Middle East and Africa Immune Checkpoint Agents Revenue by Application (2017-2028)
10.3 Middle East and Africa Immune Checkpoint Agents Market Size by Country
10.3.1 Middle East and Africa Immune Checkpoint Agents Sales by Country (2017-2028)
10.3.2 Middle East and Africa Immune Checkpoint Agents Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Corporation Information
11.1.2 Bristol Myers Squibb Overview
11.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bristol Myers Squibb Immune Checkpoint Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bristol Myers Squibb Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Immune Checkpoint Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck Immune Checkpoint Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 AstraZeneca
11.3.1 AstraZeneca Corporation Information
11.3.2 AstraZeneca Overview
11.3.3 AstraZeneca Immune Checkpoint Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 AstraZeneca Immune Checkpoint Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 AstraZeneca Recent Developments
11.4 Roche
11.4.1 Roche Corporation Information
11.4.2 Roche Overview
11.4.3 Roche Immune Checkpoint Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Roche Immune Checkpoint Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Roche Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Immune Checkpoint Agents Industry Chain Analysis
12.2 Immune Checkpoint Agents Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Immune Checkpoint Agents Production Mode & Process
12.4 Immune Checkpoint Agents Sales and Marketing
12.4.1 Immune Checkpoint Agents Sales Channels
12.4.2 Immune Checkpoint Agents Distributors
12.5 Immune Checkpoint Agents Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Immune Checkpoint Agents Industry Trends
13.2 Immune Checkpoint Agents Market Drivers
13.3 Immune Checkpoint Agents Market Challenges
13.4 Immune Checkpoint Agents Market Restraints
14 Key Findings in The Global Immune Checkpoint Agents Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer